Navigation Links
A 4-Week Therapy with Transition Therapeutics' E1-I.N.T. Leads to,Sustained Reductions in Blood Glucose Levels for 6 Months,Post-treatment in Type 2 Diabetes Patients

Final Results from Exploratory Phase IIa Clinical Trial in Type 2 Diabetes Patients Announced

TORONTO, June 28, 2007 /PRNewswire-FirstCall/ - Transition Therapeutics Inc. ("Transition") , today announces the results from its exploratory Phase IIa clinical trial indicating that 4-weeks of daily treatments with gastrin-based therapy, E1-I.N.T.(TM), showed sustained reductions in blood glucose control parameters, including haemoglobinA1C (HbA1c), for 6 months post-treatment. The type 2 diabetes patients enrolled in this study were using metformin with/without thiazolidinediones (TZD). Transition will host a conference call to discuss these data at 5:00 pm EST on Thursday June 28th, 2007.

"These data are very encouraging and show the potential of a regenerative therapy in diabetes," said Sherwyn Schwartz, MD, a noted diabetes researcher and the Director of the Diabetes & Glandular Disease Research Associates in San Antonio, Texas who was the lead investigator of the study.

"Achieving sustained improvements in glucose control for many months post-treatment following a 4-week therapy is unprecedented in type 2 diabetes. The improvements in HbA1c correlated with changes in multiple other clinical parameters suggesting that gastrin-based therapies, and specifically E1-I.N.T.(TM), have the potential to re-engage the body's natural mechanism to regulate glucose," said Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition. "The immediate goal is to optimize the dosing regimen in a larger phase II study".

Key Efficacy Findings:

As in Transition's press release on March 5th, 2007, analysis of efficacy parameters was performed on type 2 diabetes patients with HbA1c levels of equal to or greater than 7% prior to treatment.

In the E1-I.N.T.(TM) treated group of patients, the mean HbA1c level was reduced by 0.94% to 1.21% vs. baseline levels in months 2 to 6 post-treatment. Mor
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
2. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
3. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
4. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
5. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
6. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
7. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
8. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
9. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
10. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
11. MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy
Post Your Comments:
(Date:8/28/2015)... -- IP Shakti, LLC, today announced that it has changed its ... Logo - http://photos.prnewswire.com/prnh/20150827/261551LOGO ... signifies our transformation into a company focused on patent claim ... claim validity." ... platform, the Company commenced a corporate re-branding initiative in order ...
(Date:8/28/2015)... FARUM, Denmark and ATLANTA ... July 31, 2015 the US Food and Drug Administration (FDA) ... Major Depressive Disorder in adult patients who have failed to ... episode. TMS is a non-invasive technique for stimulating neural tissue ... from Major Depressive Disorder. The procedure has been proven safe ...
(Date:8/28/2015)... 2015 The report "Eubiotics Market by Type (Probiotics, ... and Aquaculture), & by Region ( North America ... , and Rest of the World) - Global Trends and ... Eubiotics was valued at USD 4.62 Billion in 2014 and ... a CAGR of 7.4% from 2015 to 2020. ...
Breaking Medicine Technology:IP Shakti, LLC Changes Company Name to Prediqtus, LLC 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 2Therapy System for Treating Major Depressive Disorder Receives FDA Clearance 3Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5
... DIEGO, Sept. 8 ResMed Inc. (NYSE: RMD ... company,s outstanding shares of common stock, payable in the form ... 2010. The new total shares outstanding doubled to 151,388,240 shares, ... the company,s common stock on the New York Stock Exchange ...
... 8 Transgenomic, Inc. (OTC Bulletin Board: ... chief executive officer, will deliver the Company,s corporate presentation ... Conference on Monday, September 13 at 4:55 p.m. EDT. ... in New York City from September 13th – 15th, ...
Cached Medicine Technology:Transgenomic to Present at the Rodman & Renshaw 12th Annual Global Investment Conference 2Transgenomic to Present at the Rodman & Renshaw 12th Annual Global Investment Conference 3
(Date:8/31/2015)... ... August 31, 2015 , ... healthbeautydistributors.com has ... services by test marketing a doctor note service to be made available to ... under $50 for each generated excuse, much less than the average daily pay ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Marietta dentists ... organ transplant issues. The doctors and staff ran a 5K race, the Iron ... Kimmerling DDS and Garrick McGrath DMD sponsored the event to help support projects with ...
(Date:8/30/2015)... ... August 31, 2015 , ... The acknowledgement from Caribbean ... by TripAdvisor earlier in 2015. The island of Providenciales itself received a TripAdvisor ... The Venetian on Grace Bay is offering a special promotion for newlyweds and honeymooners ...
(Date:8/30/2015)... ... 31, 2015 , ... Intellitec Solutions, based in Wilmington, DE, ... 5th & 6th in San Antonio, TX. Dedicated to bringing long term and ... all over the country come to share the latest and greatest in healthcare ...
(Date:8/30/2015)... (PRWEB) , ... August 30, 2015 , ... ... is pleased to announce that Partner Daniel M. Kotin was recently elected to ... exclusive organization constitutes the highest degree of peer recognition and outstanding professionalism. ...
Breaking Medicine News(10 mins):Health News:Verde Pointe Dental Associates Runs a 5K for Enduring Hearts 2Health News:Grace Bay Beach Named a Top Beach Destination for Weddings 2Health News:Intellitec Solutions to feature Microsoft Dynamics GP at AHCA/NCAL 66th Annual Convention & Expo 2Health News:Chicago Personal Injury Lawyer Daniel M. Kotin Elected to the American Board of Trial Advocates 2Health News:Chicago Personal Injury Lawyer Daniel M. Kotin Elected to the American Board of Trial Advocates 3
... Desmond Laurence, of the University of London says that ... that they compensated for any problem that // arises ... contracts that are badly worded and do not make ... British Medical Journal reported that accidental and unintentional injuries ...
... A retired doctor fond of gambling lost pounds 8million in a ... one is // that he is putting the blame on ... is suing for his money back. ,The name of ... drugs giant GlaxoSmithKline had failed to warn patients its medicine Requip ...
... health fraternity is deeply concerned. ,According to a ... full recovery from anorexia nervosa is slow, and women ... risk of death. ,As reported in International Journal ... the Klinik Roseneck Hospital for Behavioral Medicine in Prien, ...
... Centre scientists have unravelled mystery surrounding the leaf ... cancer in // animals. ,Anticancer Research journal ... treating mice with this extract before and after ... expression of a cell receptor associated with invasive ...
... found in Australia, could be used as mosquito repellents, in ... University of Adelaide gave mice the secretions of the dumpy ... minutes compared to 12 minutes for an untreated group, the ... the chemical that is used in commercial mosquito repellents, were ...
... garments that could do much more than just cover the ... // underwear that can smell like vanilla and stockings with ... that have been developed since the textile industry followed the ... with functional food. ,The garments have some additional ...
Cached Medicine News:Health News:Mystery unfolds about the Ginkgo biloba extract! 2Health News:Bio-Functional Garments That Could Revolutionize Fashion Industry 2Health News:Bio-Functional Garments That Could Revolutionize Fashion Industry 3
Immuno-turbidimetric Assay for Antithrombin III Antigen. Suspension of microlatex particles coated with specific antibodies....
Immuno-turbidimetric assay for Free Protein Sby STA© Analyzers. Suspension of microparticles coated with monoclonal antibodies to Free Protein S....
Substrate Plasma for Factor II Assay by STA© Analyzers. Freeze-dried human serum and absorbed bovine plasma, the latter providing factor V and fibrinogen to the test system....
Substrate Plasma for Factor VIII Assay by STA© Analyzers. Freeze-dried human plasma from which factor VIII has been removed by selective immuno-adsorption....
Medicine Products: